How Community Oncologists Can Break Down Biosimilar Adoption BarriersMarch 19th 2023
On this episode of Not So Different, Mark Guyot, senior director of unity provider engagement at McKesson, gives an overview of McKesson’s real-world analysis of community oncology practices and their use of biosimilars and offers advice on overcoming adoption barriers and expanding education efforts.
On the Come Up: What Vizient’s Report Says About Inflation and BiosimilarsFebruary 26th 2023
On this episode of Not So Different, Vizient’s Carina Dolan, PharmD, MS, BCOP, expounds on some of the results from Vizient’s recent edition of its Pharmacy Market Outlook Report, including how inflation could influence biosimilar utilization.
Seeing Eye to Eye: FDA's Dr Sarah Yim Discusses Efforts to Increase Confidence in Ophthalmology BiosimilarsJanuary 29th 2023
On this episode of Not So Different, the FDA’s Sarah Yim, MD, discusses how the FDA is working to improve public trust in ophthalmology biosimilars and interchangeable products as part of a 3-part multimedia interview series.
New Year, New Hurdles: What's in Store for Biosimilars in 2023December 18th 2022
On this episode, Brian Biehn, senior director of biosimilar commercialization at AmerisourceBergen, explored how the new year may play out for biosimilars, including his predictions or how uptake will be influenced in the adalimumab market and how government policies will impact the competitiveness of the market.
Biosimilars Regulatory Roundup for November 2022—Podcast EditionDecember 4th 2022
On this episode of Not So Different, we recap some of the big regulatory news to come out of November, including some progress for insulin biosimilars, the European approval of another ranibizumab biosimilar, and the congressional introduction of a US Senate bill that is seeking to nix switching study requirements for interchangeability.
What Amgen’s Biosimilar Trends Report Says About the Future of BiosimilarsNovember 27th 2022
Chad Pettit, the executive director of marketing and global biosimilars commercial lead at Amgen, discusses the most recent version of Amgen's Biosimilar Trends Report and what the report says about the current biosimilar market and how it could develop in the years to come.
Biosimilars Policy Roundup for October 2022—Podcast EditionNovember 6th 2022
On this episode of Not So Different, we recap some of the biosimilar policy news from the around the world during October, including the implementation of a biosimilars switching policy, the European Union declaration of biosimilars as interchangeable, and the reauthorization of the Biosimilars User Fee Act.
Order of Operations: Managing Biosimilars While Maintaining Operational EfficiencyOctober 16th 2022
In this podcast episode, Kathy Oubre, MS, CEO of Pontchartrain Cancer Center, discussed the stresses that practices and clinics face when trying to manage biosimilars as well as some policy considerations that administrators should keep in mind as more biosimilars enter the market and are added to formularies.
Biosimilars Oncology Roundup for September 2022—Podcast EditionOctober 2nd 2022
On this episode of Not So Different, we take a look at some of the big stories regarding oncology biosimilars throughout the month of September, including 2 FDA approvals, and the withdrawal of a European application.
What Will Year 1 Look Like for Adalimumab Biosimilars?September 11th 2022
As part of a larger series preparing for the US market entrance of adalimumab biosimilars in 2023, Steven Lucio, PharmD, BCPS, senior principal of pharmacy solutions at Vizient, makes predictions for how the rollout of these biosimilars may play out and offers advice to stakeholders for how to maintain a robust market.
Biosimilars Regulatory Roundup for August 2022—Podcast EditionSeptember 4th 2022
On this episode of Not So Different, we look back at some of the biggest regulatory events to happen in the biosimilar space during August, including 2 European approvals, 2 US approvals, and the advancement of the Inflation Reduction Act of 2022.
Tools of the Trade: How Intrafusion by McKesson Improves Infusion Center Efficiency, Biosimilar UtilizationAugust 21st 2022
Cheryl Vaughn, vice president of clinical services at McKesson, discussed how McKesson's Intrafusion service helps manage infusion sites and aids in the administration of complex biologic drugs, including biosimilars.
Not So Different: Biosimilars Oncology Roundup for July 2022—Podcast EditionAugust 7th 2022
On this episode of Not So Different, we recap some of the biggest biosimilars news that happened over the past month, including updates on clinical trials for oncology biosimilars as well as a survey on whether patients were given adequate information prior to switching a biosimilar.
Not So Different: How Health Policies May Take Shape in a Post-Humira-Exclusive Adalimumab MarketJuly 24th 2022
On this podcast episode, The Center for Biosimilars spoke with Chronis Manolis from UPMC Health Plan to discuss how health care policies may shift as adalimumab biosimilars referencing Humira come to market in 2023, including how providers and payers can ensure equitable access.
New Biosim on the Block: Dr Sonia Oskouei Discusses the US Launch of Byooviz, the First Ophthalmology BiosimilarJuly 10th 2022
On this episode of Not So Different, we spoke with Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars at Cardinal Health, to discuss the US launch of Byooviz, the first ophthalmology biosimilar in the United States, and how it's expected to impact ophthalmology care.
STADA, Alvotech Launch Adalimumab Biosimilar in First Few European CountriesJune 10th 2022
STADA Arzneimittel and Alvotech announced the launch of their high-concentration, citrate-free adalimumab biosimilar (Hukyndra) in France, Germany, Finland, and Sweden, with more European countries to come.
Not So Different: Tactics for Increasing Patient and Provider Confidence in BiosimilarsOctober 10th 2021
Kirollos Hanna, PharmD, from the University of Minnesota Medical Center, explains how his practice has worked to inform patients and providers about biosimilars and improve their confidence in the utilization of biosimilars.
Not So Different: How One Practice Is Addressing Biosimilar Concerns Over Savings, Safety, and EfficacyOctober 3rd 2021
Kirollos Hanna, PharmD, from the University of Minnesota Medical Center, talks about the savings that biosimilars have brought to his practice and how he tackles patient and physician concerns over whether biosimilars work as well as reference products.
Not So Different: How Biosimilar Companies Are Stepping Up Their Game to Compete Against OriginatorsSeptember 19th 2021
Kirollos Hanna, PharmD, from the University of Minnesota Medical Center, discusses some of the tactics that biosimilar companies are employing in order to level the playing field and better compete against originator companies.
Not So Different: Dr Gary Lyman Explains How to Ensure Physician Confidence in BiosimilarsAugust 15th 2021
Gary Lyman, MD, MPH, an oncologist and hematologist, discusses some of the issues holding physicians back from prescribing biosimilars and some ways to ensure provider confidence in biosimilars.
Not So Different: What the Generics Industry Can Tell Us About the Future of BiosimilarsJuly 18th 2021
On this week’s episode of Not So Different, we spoke with David Senior, senior vice president of Market Economics at AmerisourceBergen, about the development of the generics market and how this could be instructive in understanding how biosimilars sales may develop.
Not So Different: How Henlius is Making Its Mark on the Global Biosimilar IndustryJune 20th 2021
Ping Cao, vice president of Business Development for Shanghai Henlius Biotech, discussed the company's current biosimilar development plans and the process for getting regulatory approval for biosimilars in China.